Evidence map›Paper›PMID 40907950›Full record

ArticleJournal of medicinal chemistry2025

Ruthenocenyl and 1-Adamantyl Paclitaxel Analogs Disrupt the Balance between βIII- and βIVa-Tubulin and Inhibit the Growth and Invasiveness of Colon Cancer.

Wojciech M Ciszewski, Karolina Kowalczyk, Andrzej Błauż, Wojciech Ciesielski, Piotr Hogendorf, Beata Smolarz, Waldemar Wagner, Anna Wieczorek-Błauż, Błażej Michał Rychlik, Hanna Romanowicz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wojciech M CiszewskiDepartment of Molecular Cell Mechanisms, Medical University of Lodz, Mazowiecka 6/8, Lodz 92-215, Poland.
Karolina KowalczykLaboratory of Molecular Spectroscopy, Department of Organic Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, Lodz 91-403, Poland.
Andrzej BłaużCentre for Digital Biology and Biomedical Science - Biobank Lodz, Faculty of Biology and Environmental Protection, University of Lodz, ul. Pomorska 141/143, Łódź 90-236, Poland.
Wojciech CiesielskiDepartment of General and Transplant Surgery, Medical University of Lodz, Kopcinskiego 22, Lodz 90-419, Poland.
Piotr HogendorfDepartment of General and Transplant Surgery, Medical University of Lodz, Kopcinskiego 22, Lodz 90-419, Poland.
Beata SmolarzLaboratory of Cancer Genetics, Department of Pathology, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, Lodz 93-338, Poland.
Waldemar WagnerLaboratory of Cellular Immunology, Institute of Medical Biology PAS, Lodowa 106, Lodz 93-232, Poland.
Anna Wieczorek-BłaużDepartment of Organic Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, Lodz 91-403, Poland.ORCID 0000-0001-8332-9757
Błażej Michał RychlikCentre for Digital Biology and Biomedical Science - Biobank Lodz, Faculty of Biology and Environmental Protection, University of Lodz, ul. Pomorska 141/143, Łódź 90-236, Poland.ORCID 0000-0001-8928-5900
Hanna RomanowiczLaboratory of Cancer Genetics, Department of Pathology, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, Lodz 93-338, Poland.
Adam DurczyńskiDepartment of General and Transplant Surgery, Medical University of Lodz, Kopcinskiego 22, Lodz 90-419, Poland.
Katarzyna SobierajskaDepartment of Molecular Cell Mechanisms, Medical University of Lodz, Mazowiecka 6/8, Lodz 92-215, Poland.
Damian PlażukLaboratory of Molecular Spectroscopy, Department of Organic Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, Lodz 91-403, Poland.ORCID 0000-0002-2898-6604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Taxanes are widely used anticancer agents that stabilize microtubules and arrest cell division. However, their efficacy in colon cancer is limited by the chemoresistance associated with βIII-tubulin (TUBB3) upregulation. Herein, ferrocenyl, ruthenocenyl, and 1-adamantyl analogs of paclitaxel were synthesized and biologically evaluated. All compounds exhibited significantly higher cytotoxicity than paclitaxel, with IC

Indexed as

AdamantaneAntineoplastic AgentsColonic NeoplasmsPaclitaxelTubulinTubulin ModulatorsCell Line, TumorCell ProliferationHumansNeoplasm InvasivenessStructure-Activity RelationshipAdamantaneAntineoplastic AgentsPaclitaxelTubulinTubulin Modulators

Identifiers

PMID40907950
PMCPMC12481480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.